Key Market Indicator:
F&G: 52
25.060,90 NASDAQ · 48.619,99 DOW · 6.825,55 S&P · 4.865,99 Gold · 63,63 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© BusinessWire
07.01.2025
ISIN: US8292141053
Simulations Plus Inc
SLP
LISTED
NASDAQ
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
Article
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Article
News Preview
LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com. The Company has achieved several key mileston...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Article
News Preview
LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com. The Company has achieved several key mileston...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
07.01.2025
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
Article
News Preview
Press Release – No. 2 / 2025...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
07.01.2025
ISIN: SE0000135485
RaySearch Laboratories AB (publ)
RAY B
LISTED
STO
RaySearch receives first order for DrugLog
Article
News Preview
STOCKHOLM, Jan. 7, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) today announces that the Polish company Medim has placed an order for the product DrugLog™. The order is a result of Medim winning a tender from The Children's Memorial Health Institute in Warsaw, Poland. DrugLog is RaySearch's cost-effective solution for quickly and effic...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA. Company Presentation | Tempus Founder and CEO, Eric Lefkofsky, will deliver a presentation and host a Q&A with...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
Article
News Preview
Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565,...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 20...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST. Any changes to this event and links to the live webcast will be posted on the In...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide
Article
News Preview
ORION CORPORATION INVESTOR NEWS 7 JANUARY 2025 at 9:00 EET...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ISIN: BE0003874915
Fagron NV
FAGR
LISTED
EURONEXT
Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil
Article
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM CET...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
ISIN: US8793691069
Teleflex Inc
TFX
LISTED
NYSE
Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated (TFX)
Article
News Preview
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Teleflex stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ActuNews
06.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIË – 6 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparan...
Themefolio
Profiler
Peergroup
© ActuNews
06.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIUM – January 6, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on January 6, 2025, from At...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
ISIN: US74039M3097
Predictive Oncology, Inc.
POAI
LISTED
NASDAQ
POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders
Article
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQ: POAI) to Renovaro Inc. is fair to Predictive shareholders. Halper Sadeh encourages Predictive shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
Article
News Preview
Press Release – No. 1 / 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
ISIN: GB00BYMT0J19
LivaNova PLC
LIVN
LISTED
NASDAQ
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
Article
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. “Natalia...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
ISIN: US2290503075
Cryoport Inc
CYRX
LISTED
NASDAQ
Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA")
Article
News Preview
All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn., Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological Solutions ("MVE"), a Cry...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ISIN: US74039M3097
Predictive Oncology, Inc.
POAI
LISTED
NASDAQ
Predictive Oncology Announces Agreement to be Acquired by Renovaro
Article
News Preview
- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ISIN: US45258D1054
Immunocore Holdings plc
IMCR
LISTED
NASDAQ
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
Media ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 14, 2025, 12:00 AM CET on January 15, 2025. The live and archived webcast of t...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
Article
News Preview
Atlas Special Opportunities, LLC heeft 6 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 150.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Article
News Preview
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIË – 3 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transparan...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIUM – January 3, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on December 30, 2024, from...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
ISIN: US5588681057
Madrigal Pharmaceuticals Inc
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relati...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
ISIN: DK0060336014
Novozymes A/S
NSIS B
LISTED
CPH
Trading by management and close relations of management
Article
News Preview
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.01.2025
ISIN: US45258D1054
Immunocore Holdings plc
IMCR
LISTED
NASDAQ
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Article
News Preview
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
Article
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025. Summarized terms for the...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
Article
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025. Summarized terms for the...
Themefolio
Profiler
Peergroup
© ActuNews
31.12.2024
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion kondigt uitstel aan van ondertekening van strategische transactie wegens lopende besprekingen
Article
News Preview
Leuven, België – 31 december 2024 – 18u00 CET - Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt een kort uitstel aan van ongeveer vier weken voor de ondertekening van de voorgenomen strategische transactie. Dit uitstel is het gevolg van lopende besprekingen tussen de partijen, in...
Themefolio
Profiler
Peergroup
© ActuNews
31.12.2024
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Announces Postponement of Signing for Strategic Transaction Due to Ongoing Discussions
Article
News Preview
LEUVEN, BELGIUM –31 December 2024 – 6:00PM, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces a short postponement of approximately four weeks for the signing of its contemplated strategic transaction. The delay is due to ongoing discussions between the parties, prompted by the better t...
Themefolio
Profiler
Peergroup
© ActuNews
31.12.2024
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion annonce le report de la signature de la transaction stratégique en raison de discussions en cours
Article
News Preview
Louvain, BELGIQUE – 31 décembre 2024 – 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce un léger report d'environ quatre semaines de la signature de la transaction stratégique envisagée. Ce report est dû à des discussions en co...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.12.2024
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
IBA - Information réglementée
Article
News Preview
Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (M.B. 12.VI.2007) (ci-après, la « Loi »)...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
ISIN: US68232V8019
Traws Pharma Inc.
TRAW
LISTED
NASDAQ
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Article
News Preview
Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term value inflecting readouts NEWTOWN, Pa., Dec. 30, 2024 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a cl...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.12.2024
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 43rd Annual J.P. Morg...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
Article
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
Article
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.12.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Article
News Preview
Company announcement – No. 53 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.12.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
Article
News Preview
Company announcement – No. 52 / 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
Article
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine’s 2024 list of World’s Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in it...
Themefolio
Profiler
Peergroup
© PR Newswire
23.12.2024
ISIN: US68232V8019
Traws Pharma Inc.
TRAW
LISTED
NASDAQ
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
Article
News Preview
Investigational agent in development for treatment or prevention of H5N1 Bird Flu Phase 1 dosing completed in healthy volunteers   Potent inhibition of drug-resistant and bird flu viruses in vitro In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs Phas...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
ISIN: US45258D1054
Immunocore Holdings plc
IMCR
LISTED
NASDAQ
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Article
News Preview
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
ISIN: BE0003874915
Fagron NV
FAGR
LISTED
EURONEXT
Fagron updates on FDA communication regarding the June 2024 inspection at Wichita
Article
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Article
News Preview
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement re...
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia discovery study published in top protein research journal
Article
News Preview
LUND, Sweden, Dec. 20, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
Article
News Preview
Company announcement – No. 51 / 2024...
Themefolio
Profiler
Peergroup
© ActuNews
19.12.2024
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
OXURION : Franse autoriteiten keuren de strategische transactie van Oxurion goed onder specifieke voorwaarden
Article
News Preview
Leuven, België – 19 december 2024 – 18u00 CET - Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt aan dat het Franse Ministerie van Economie, Financiën en Industrie de voorgenomen strategische transactie van de vennootschap heeft goedgekeurd. De voorgenomen transactie, een bel...
Themefolio
Profiler
Peergroup
© ActuNews
19.12.2024
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
OXURION : Les autorités françaises approuvent la transaction stratégique d'Oxurion, sous certaines conditions spécifiques
Article
News Preview
Louvain, BELGIQUE – 19 décembre 2024 – 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce que le Ministère français de l'Économie, des Finances et de l'Industrie a approuvé la transaction stratégique envisagée par la...
Themefolio
Profiler
Peergroup
© ActuNews
19.12.2024
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
OXURION : French Authorities Approve Oxurion's Strategic Transaction Under Specific Conditions
Article
News Preview
LEUVEN, BELGIUM – 19 December 2024 – 6:00PM, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces that the French Ministry of the Economy, Finance and Industry has approved the Company's contemplated strategic transaction. The contemplated transaction, which is a significant step in Ox...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Article
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS19 DECEMBER 2024 at 19.00 EET...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding
Article
News Preview
LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025. In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success As 2024 began, we had recently completed a significant transformation...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ISIN: GB0009223206
Smith & Nephew PLC
SN
LISTED
LSE
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty
Article
News Preview
Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ISIN: US52490G1022
Legend Biotech Corp
LEGN
LISTED
NASDAQ
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday,...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
ISIN: CA60255C8850
Definium Therapeutics, Inc.
DFTX
LISTED
NASDAQ
MindMed to Be Added to the Nasdaq Biotechnology Index
Article
News Preview
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transform...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
Article
News Preview
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference on Thursday, January 16, 2025,...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
Article
News Preview
STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone
Article
News Preview
STOCKHOLM, SWEDEN – December 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 23.8 million through a convertible loan to be used for the continuation of the company’s clinical study of golexanolone in primary biliary cholangitis. The convertible loan with attac...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
Article
News Preview
STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Wednesday, 21.01.2026, Calendar Week 04, 21st day of the year, 344 days remaining until EoY.